Total Payments
$3.3M
2024 Payments
$39,190
Companies
9
Transactions
851
Payment Breakdown by Category
Consulting$3.3M (99.9%)
Research$3,605 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3.3M | 849 | 99.9% |
| Unspecified | $3,605 | 2 | 0.1% |
Payments by Type
General
$3.3M
849 transactions
Research
$3,605
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $1.6M | 516 | $0 (2021) |
| PFIZER INC. | $1.5M | 244 | $0 (2024) |
| MEDIVATION INC. | $181,960 | 54 | $0 (2020) |
| Astellas Pharma Global Development | $55,400 | 6 | $0 (2018) |
| Incyte Corporation | $4,235 | 2 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $3,605 | 2 | $0 (2019) |
| Janssen Research & Development, LLC | $3,440 | 2 | $0 (2017) |
| Gilead Sciences, Inc. | $2,925 | 14 | $0 (2019) |
| SANOFI US SERVICES INC. | $2,700 | 11 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,190 | 13 | PFIZER INC. ($35,810) |
| 2023 | $52,745 | 13 | PFIZER INC. ($51,890) |
| 2022 | $82,580 | 12 | PFIZER INC. ($82,480) |
| 2021 | $315,440 | 116 | PFIZER INC. ($181,200) |
| 2020 | $563,150 | 178 | Merck Sharp & Dohme Corporation ($344,840) |
| 2019 | $583,485 | 176 | Merck Sharp & Dohme Corporation ($346,390) |
| 2018 | $895,028 | 172 | PFIZER INC. ($488,250) |
| 2017 | $780,543 | 171 | Merck Sharp & Dohme Corporation ($432,523) |
All Payment Transactions
851 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $5,830.00 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,720.00 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $3,380.00 | General |
| 09/17/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,610.00 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,680.00 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,370.00 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,390.00 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $7,310.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $1,270.00 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,140.00 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,350.00 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $855.00 | General |
| 08/22/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,680.00 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,150.00 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,120.00 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,980.00 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $6,170.00 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,760.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PCYC-1142-CA | Pharmacyclics LLC, An AbbVie Company | $3,355 | 1 |
| PCYC-1127-CA | Pharmacyclics LLC, An AbbVie Company | $250.00 | 1 |
About Dr. Cheryl Sadow, MD
Dr. Cheryl Sadow, MD is a Body Imaging healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1891772588.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cheryl Sadow, MD has received a total of $3.3M in payments from pharmaceutical and medical device companies, with $39,190 received in 2024. These payments were reported across 851 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($3.3M).
Ad
Practice Information
- Specialty Body Imaging
- Other Specialties Diagnostic Radiology
- Location Boston, MA
- Active Since 12/23/2005
- Last Updated 09/12/2012
- Taxonomy Code 2085B0100X
- Entity Type Individual
- NPI Number 1891772588
Products in Payments
- KEYTRUDA (Biological) $1.6M
- XTANDI (Drug) $545,385
- BAVENCIO (Drug) $467,540
- TALZENNA (Drug) $372,640
- ENZALUTAMIDE (Drug) $55,400
- Ibrutinib (Drug) $3,605
- ZYTIGA (Drug) $3,440
- CERDELGA (Drug) $2,700
- DAURISMO (Drug) $250.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Body Imaging Doctors in Boston
Dr. Nisha Sainani, M.d, M.D
Body Imaging — Payments: $2.9M
Body Imaging $2.9M
Milos Janicek, M.d, M.D
Body Imaging — Payments: $48,877
Body Imaging $48,877
Aran Toshav, Md, MD
Body Imaging — Payments: $13,642
Body Imaging $13,642
Donna-Lee Selland, Md, MD
Body Imaging — Payments: $2,735
Body Imaging $2,735
Dr. Olga Brook, Md, MD
Body Imaging — Payments: $1,466
Body Imaging $1,466
John Santilli, Md, MD
Body Imaging — Payments: $654.82
Body Imaging $654.82